Data & profiles

Data & profiles

Access our comprehensive repository of country-level and sub-national hepatitis data from stakeholders including the World Health Organization, UNICEF, the Institute for Health Metrics and Evaluation, and local Ministries of Health. Data includes epidemiological, program monitoring, and policy environment metrics, such as availability of strategic action plans and testing policies, as well as target year for elimination. 

View individual country/region data dashboards in the drop-down list below. 

As of 2019, 354 million persons are living with chronic hepatitis B (HBV) or C (HCV) virus infection. Of these 354 million persons, 87% are unaware of their infection and 95% have not been treated.

Hepatitis B:

  • Number of persons living with HBV in 2019: 295.9 million
  • Number of HBV-related deaths in 2019: 821,100
  • Proportion of persons living with HBV aware of their infection in 2019: 10.3% (with the highest rates in the European (18.7%), Western Pacific (18.5%), and the Americas (18.5%) regions, whereas the lowest rates were in the African (2·2%) and the South-East Asia (2.1%) regions)
  • Proportion of persons living with HBV on treatment in 2019: 2.2% (of those eligible) 

Hepatitis C:

  • Number of persons living with HCV in 2019: 57.8 million
  • Number of HCV-related deaths in 2019: 287,700
  • Proportion of persons living with HCV aware of their infection in 2019: 21.4% (with the highest rates in the Eastern Mediterranean region (37%), followed by the Western Pacific region (25%), and the lowest in the African region (5%), followed by the South-East Asia region (7%)).
  • Proportion of persons living with HCV who were treated 2015-2019: 13.2% (of the 71 million persons living with HCV in 2021)

Source: Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, Séguy N, Rewari BB, Chan PL, Le LV, Doherty M, Luhmann N, Easterbrook P, Dirac M, de Martel C, Nayagam S, Hallett TB, Vickerman P, Razavi H, Lesi O, Low-Beer D. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8. PMID: 36764320.

Overview

Page last updated: 09 February 2024